🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Read our article "Lipoprotein(a) – From Biomarker to Therapy: A Review for the Clinician." Our review covers its clinical significance, emerging therapies, the latest guidelines on screening and management! ajconline.org/article/S0002-… Eli Gelfand, MD, FACC Inbar McCarthy MD FACC

7% of all patients in US emergency departments underwent cardiac biomarker testing, with variability in testing practices. Cian McCarthy Nathan Watson, MD Eric Secemsky MD MSc ja.ma/4hf4bTk

In this weeks edition of JACC Journals, Dr. Shah and colleagues explore the use of hs-cTn in CVD risk prediction for primary prevention. jacc.org/doi/10.1016/j.… Drs. Januzzi, John William McEvoy, and I discuss the implication of their findings. jacc.org/doi/10.1016/j.…

Our new meta-analysis in JACC Journals Harlan Krumholz led by Anoop Shah: Cardiac Troponins and CV Risk Prediction! Measurement of cardiac troponin results in a modest improvement in the prediction of first-onset CVD. jacc.org/doi/full/10.10… CTCPR Trials & CIRL RigsHeart 🫀🚨 Dr. Deepak L. Bhatt

Today means everything

Dreams do come true.

The TARGET-Type 2 pilot RCT demonstrates it is feasible to randomise patients with Type 2 MI to CTCA and echocardiography guided treatment of coronary artery disease and LV impairment 🧵sciencedirect.com/science/articl…

Ever get annoyed working up mildly elevated troponins in older adults who do not have signs of myocardial ischemia? Turns out many of those ‘mildly elevated’ troponins in persons in 70s and 80s are likely within NORMAL RANGE for their age. Huge issue! academic.oup.com/eurheartj/adva…

NIPC University of Galway CMNHS Johns Hopkins Ciccarone Center led by Cian McCarthy Regulatory Approval vs Guideline Endorsement of Novel BP-Lowering Treatments jamanetwork.com/journals/jamac…

After 20 years of static development, 3 novel BP ⬇️ therapies were FDA approved in 2024. Now in JAMA Cardiology, led by ⭐️ UMass Chan Medical School student Ritika Revoori, we discuss whether BP surrogate endpoint trials are sufficient for endorsement. John William McEvoy jamanetwork.com/journals/jamac…

In this Viewpoint, Cian McCarthy and colleagues advocate for cardiovascular disease outcome trials for new BP lowering treatments targeting novel pathways. ja.ma/3H6NBsg

Last dinner as an Advanced Cardiac Imaging fellow. Grateful for amazing colleagues, inspiring mentors, and a world-class hospital. Onward, with deep gratitude. ❤️🫀 #FellowshipGraduation #CardiacImaging #MGH MGH Cardiovascular Imaging Research Center

While this content may seem obvious @ first, I humbly believe the idea is more nuanced than first glance and rather profound. Led by Cian McCarthy. NIPC Roger Blumenthal Reflections on Binary Thresholds for Hypercholesterolemia and Hypertension | JACC jacc.org/doi/10.1016/j.…

Now in JACC Journals, John William McEvoy and I discuss approaches to defining hypercholesterolemia and hypertension in an era of CVD risk based treatment allocation. jacc.org/doi/full/10.10…

Now in JACC Journals, Thijs Eijsvogels and colleagues find that most exercise induced troponin elevation is not explainable by CAD. jacc.org/doi/10.1016/j.… Meagan Murphy Wasfy and I contextualize these results in accompanying editorial Mass General Heart jacc.org/doi/10.1016/j.…

Our paper on #cardiac #troponins and #coronary #atherosclerosis in Masters #athletes just got published in JACC Journals. Download your copy via: authors.elsevier.com/a/1lH6h2d9GI28… #sportscardio #exercise #prevention